Your session is about to expire
← Back to Search
Atorvastatin for Hearing Loss in Head and Neck Cancer
Study Summary
This trial will study whether atorvastatin reduces hearing loss in people treated with cisplatin and radiation for head and neck squamous cell carcinoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have squamous cell carcinoma of the head and neck and will be treated with specific chemotherapy and radiation.Your blood test results for AST, ALT, CPK, and creatinine are too low.I am currently taking a statin medication.I can make my own medical decisions and have signed the consent form.I can take pills by mouth or feeding tube and will follow the daily medication plan.I am currently taking cimetidine, spironolactone, ketoconazole, cyclosporine, or protease inhibitors.I am scheduled for more chemotherapy after my current treatment for cancer in the nose and throat area.I am willing and able to follow all study requirements and be available for its duration.I have been treated with platinum-based chemotherapy before.You need to have fairly good hearing in at least one ear, with a specific level of hearing ability at different pitches.You have cochlear implants in both ears.I will be taking aminoglycoside antibiotics soon.I am over 18 years old.I am 18 years old or older.You have a specific type of ear test result called a flat, Type B tympanogram.
- Group 1: 1
- Group 2: 2
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the FDA sanction this medication?
"This proposed treatment has previously been proven both effective and safe in a Phase 3 trial, thus it receives a 3 on our safety scale."
Are researchers looking for more participants in this trial?
"This trial is no longer recruiting patients. The listing was created on November 9th, 2022 and was last updated on November 3rd, 2022. However, there are 666 other trials for patients with hearing loss and 73 other trials for this treatment that are actively recruiting patients."
What are some common reasons why patients receive this type of care?
"This treatment can help manage lipidemias, postoperative thromboembolism, and anginal pain."
What is the estimated patient pool for this clinical trial?
"As of right now, this clinical trial is not looking for any more participants. This study was initially posted on November 9th, 2022 and was edited for the last time on November 3rd, 2022. If you need assistance finding other studies, there are 666 trials recruiting patients with hearing loss and 73 trials recruiting patients for this specific treatment."
Does this clinical trial break new ground?
"Since 2005, this medication has been under continuous scrutiny by the medical community. The first study, sponsored by Merck Sharp & Dohme LLC, took place in 2005 with 80 patients. After the Phase 4 drug approval in 2005, there are now 73 live studies with this treatment in 162 cities and 28 countries."
Share this study with friends
Copy Link
Messenger